Brokerages Expect Acasti Pharma Inc (NASDAQ:ACST) Will Announce Earnings of -$0.11 Per Share
Equities analysts expect that Acasti Pharma Inc (NASDAQ:ACST) will report earnings of ($0.11) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Acasti Pharma’s earnings. Acasti Pharma posted earnings per share of ($0.18) during the same quarter last year, which would indicate a positive year over year growth rate of 38.9%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 13th.
On average, analysts expect that Acasti Pharma will report full-year earnings of ($0.24) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.13). For the next financial year, analysts expect that the company will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.17) to ($0.04). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Acasti Pharma.
ACST has been the topic of several recent analyst reports. ValuEngine upgraded shares of WPP from a “sell” rating to a “hold” rating in a research report on Wednesday, June 19th. HC Wainwright reiterated a “buy” rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Zacks Investment Research cut shares of Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. Finally, Aegis initiated coverage on shares of Acasti Pharma in a research report on Tuesday. They set a “buy” rating on the stock.
Shares of Acasti Pharma stock traded up $0.01 on Friday, hitting $1.41. 5,600 shares of the company traded hands, compared to its average volume of 1,693,287. The firm has a market cap of $110.64 million, a PE ratio of -1.99 and a beta of 1.15. Acasti Pharma has a 52 week low of $0.43 and a 52 week high of $1.80. The company’s 50-day moving average price is $1.04.
About Acasti Pharma
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Featured Story: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.